About Arbor Biotechnologies
Arbor Biotechnologies is a company based in Cambridge (United States) founded in 2016 by David Scott and Winston Yan. Arbor Biotechnologies has raised $304.1 million across 4 funding rounds from investors including Vertex Pharmaceuticals, T. Rowe Price and Temasek. The company has 117 employees as of December 31, 2022. Arbor Biotechnologies has completed 1 acquisition, including Serendipity Biosciences. Arbor Biotechnologies offers products and services including Gene Editing Toolbox and Pipeline Products. Arbor Biotechnologies operates in a competitive market with competitors including Singleron, Octant, Diagenode, Factor Bioscience and Novomics, among others.
- Headquarter Cambridge, United States
- Employees 117 as on 31 Dec, 2022
- Founders David Scott, Winston Yan
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Arbor Biotechnologies, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$304.1 M (USD)
in 4 rounds
-
Latest Funding Round
-
Investors
Vertex Pharmaceuticals
& 26 more
-
Employee Count
117
as on Dec 31, 2022
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Arbor Biotechnologies
Arbor Biotechnologies offers a comprehensive portfolio of products and services, including Gene Editing Toolbox and Pipeline Products.
Provides tools for developing next-generation gene editing treatments.
Advances gene editing for various genetic disease applications.
People of Arbor Biotechnologies
Unlock access to complete
Unlock access to complete
Funding Insights of Arbor Biotechnologies
Arbor Biotechnologies has successfully raised a total of $304.1M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Last Round
-
First Round
First Round
(02 Aug 2017)
- Investors Count 27
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2025 | Amount | Series C - Arbor Biotechnologies | Valuation |
investors |
|
| Mar, 2025 | Amount | Series C - Arbor Biotechnologies | Valuation | Arch Venture Partners , TCG Crossover | |
| Nov, 2021 | Amount | Series B - Arbor Biotechnologies | Valuation | Temasek , TCG Crossover |
Investors in Arbor Biotechnologies
Arbor Biotechnologies has secured backing from 27 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Vertex Pharmaceuticals, T. Rowe Price and Temasek.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on life science companies
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
PE firm investing in South Korea and the US
|
Founded Year | Domain | Location |
Investments & Acquisitions by Arbor Biotechnologies
Arbor Biotechnologies has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Serendipity Biosciences.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Gene-editing technology and genetic medicines are developed for therapeutic uses.
|
0 |
Financial Statements - Arbor Biotechnologies
Arbor Biotechnologies Comparisons
Competitors of Arbor Biotechnologies
Arbor Biotechnologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Singleron, Octant, Diagenode, Factor Bioscience and Novomics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of single-cell multi-omics platform for clinical research and molecular diagnosis
|
|
| domain | founded_year | HQ Location |
Human cell interaction platform is provided for drug discovery.
|
|
| domain | founded_year | HQ Location |
Reagents and kits for epigenetics sequencing solutions are developed.
|
|
| domain | founded_year | HQ Location |
Genomic technologies are developed to treat diseases and enhance health.
|
|
| domain | founded_year | HQ Location |
Molecular diagnosis systems for cancer treatment are developed.
|
Frequently Asked Questions about Arbor Biotechnologies
Arbor Biotechnologies was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Arbor Biotechnologies is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Arbor Biotechnologies is a funded company, having raised a total of $304.1M across 4 funding rounds to date. The company's 1st funding round was a Series B of $215M, raised on Aug 02, 2017.
As of Dec 31, 2022, the latest employee count at Arbor Biotechnologies is 117.
Arbor Biotechnologies was founded in 2016 in Cambridge, United States, within the biotechnology sector. A platform is operated that integrates artificial intelligence, genome sequencing, gene synthesis, and high-throughput screening to facilitate protein discovery. A new CRISPR enzyme has been identified through this platform. Operations focus on advancing genomic tools for research and therapeutic development in the life sciences field.
Arbor Biotechnologies offers Gene Editing Toolbox and Pipeline Products.
Arbor Biotechnologies has made 1 acquisition, including Serendipity Biosciences.
Arbor Biotechnologies has 27 investors. Key investors include Vertex Pharmaceuticals, T. Rowe Price, Temasek, Janus Henderson Investors, and Piper Sandler.